オプションチェーンは、Cushman & Wakefieldの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cushman & Wakefieldの市場センチメントを評価します。.

Cushman & Wakefield (NYSE:CWK) 株価情報, オプションチェーン

Cushman & Wakefield

Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.

Cushman & Wakefield PLC

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially

News

Reported Sunday, 10x Genomics Reports $610.8M In 2024 Revenue (-1% YoY), $165M Q4 Revenue (-10% YoY), And $393M In Cash Reserves

Tesla Inc. CEO Elon Musk endorsed calls for Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) to release its content moderation communications with government officials, responding &#8220;That would be good&#8221; to prominent tech investor Dave Lee&#8216;s demand for transparency.
What Happened: &#8220;If Zuck is serious then let&#8217;s see the <a href="https://www.benzinga.com/government/22/12/30119008/elon-musks-twitter-files-part-6-drops-company-acted-as-fbis-subsidiary-a-one-big-happy-family-vibe">equivalent of the Twitter Files</a> for Facebook. Show all the communication back and forth (not just handpicked ones) between the government and Facebook regarding COVID/vaccine censorship,&#8221; Lee wrote on X, drawing Musk&#8217;s support.
The Twitter Files were a <a href="https://www.benzinga.com/news/22/12/29949435/twitter-files-revealed-musk-reacts-to-exposure-of-company-response-to-hunter-biden-story">series of internal Twitter documents </a>that were released in 2022–2023 by journalists and authors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That would be good <a href="https://t.co/Fkmj5ctjr5">https://t.co/Fkmj5ctjr5</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1878693613313663295?ref_src=twsrc%5Etfw">January 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The exchange comes as Meta CEO Mark Zuckerberg announced plans to adopt a feature similar to X&#8217;s Community Notes, signaling a major shift in <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">content moderation strategy</a>. During a video announcement, Zuckerberg acknowledged past censorship mistakes and outlined plans to &#8220;get back to our roots around free expression on Facebook and Instagram.&#8221;
Meta&#8217;s internal data reveals the scope of <a href="https://www.benzinga.com/tech/25/01/42779753/mark-zuckerbergs-meta-replaces-global-affairs-chief-nick-clegg-with-republican-joel-kaplan-ahead-of-trump-inauguration">current moderation practices</a>, with Joel Kaplan, the company&#8217;s new head of global affairs, disclosing that 10-20% of December&#8217;s content removals may have been erroneous. The platform&#8217;s pivot includes phasing out third-party fact-checkers and relocating trust and safety teams <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">from California to Texas</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42938119/lockheed-martin-donates-1m-to-trumps-inaugural-committee-as-speculation-grows-over-elon-musk-led-doge-crackdown-on-traditional-defense-contracts">Lockheed Martin Donates $1M To Trump&#8217;s Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts</a>
Why It Matters: The changes follow Zuckerberg&#8217;s recent $1 million donation to President-elect Donald Trump&#8216;s inauguration fund and their November meeting at Mar-a-Lago. During a Joe Rogan podcast appearance, Zuckerberg detailed past tensions with President Joe Biden&#8216;s administration officials, describing instances where they &#8220;would call up our team and, like, scream at them and curse&#8221; over <a href="https://www.benzinga.com/25/01/42931361/mark-zuckerberg-says-biden-officials-berated-meta-staff-as-they-refused-to-remove-true-content-it-just-got-to-this-pointthats-ridiculous">content removal requests</a>.
X CEO Linda Yaccarino praised Meta&#8217;s decision, calling it a &#8220;smart move by Zuck&#8221; and suggesting other <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">platforms would follow</a>. 
The platform&#8217;s transformation includes adding three <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">new board members</a>, including Trump ally Dana White, indicating strategic alignment with the incoming administration and a marked departure from its previous content moderation approach during the COVID-19 pandemic and 2020 election cycle.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms">US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Social Media

Markets

Tech

TSLA

Elon Musk Urges Mark Zuckerberg To Release Facebook Files, Calls It 'Good' After Meta Adopts X's Community Notes-Like Feature

<ul>
<li>New biomarkers on track for commercial launch in January 2025</li>
<li>Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn</li>
</ul>

Reported Earlier, Exagen Expects $55.3M-$55.8M In Annual Revenue (+33% YoY), And Narrowed EBITDA Loss Of $9.8M–$10.8M In 2024; For Q4 Sees $13.3M-$13.8M In Revenue

<ul>
<li>Revenue of $1,021.8 Million Grows 0.9% --</li>
<li>-- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance –</li>
<li>– GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges –</li>
</ul>

HOLX

Reported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) to report a quarterly loss at 16 cents per share on revenue of $125.53 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Comtech Telecommunications shares gained 3.9% to $4.29 in after-hours trading.</li>
<li>WD-40 Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) posted better-than-expected results for its first quarter and reiterated its FY25 guidance on Friday. WD-40 shares gained 5.5% to $254.00 in the after-hours trading session.</li>
<li>Analysts are expecting KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) to post quarterly earnings at $2.45 per share on revenue of $1.99 billion. The company will release earnings after the markets close. KB Home shares gained 0.1% to $63.25 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Nordstrom Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) said total company net sales rose 4.9%, while comparable sales increased 5.8% for the nine-week holiday period ended Jan. 4. The company also said it sees comparable sales growth of 2.5% to 3.5% versus 52 weeks in fiscal 2023, up from its previous guidance of 1.0% to 2.0% growth. Nordstrom shares gained 0.2% to $24.05 in the after-hours trading session.</li>
<li>Analysts expect ServiceTitan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) to post a quarterly loss at 3 cents per share on revenue of $198.52 million after the closing bell. ServiceTitan shares gained 0.1% to $101.40 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Trading Ideas

CMTL

TTAN

WDFC

WD-40 Company, KB Home And 3 Stocks To Watch Heading Into Monday

<h3>Companies Reporting Before The Bell</h3>
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $125.53 million. 
<h3>Companies Reporting After The Bell</h3>
• Calamos Glb Total (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGO#NASDAQ">CGO</a>) is estimated to report quarterly earnings at $2.88 per share on revenue of $770.40 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its third quarter. 
• KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) is likely to report quarterly earnings at $2.47 per share on revenue of $1.98 billion. 
• Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $15.04 million. 
• Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) is expected to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

EDUC

Earnings Scheduled For January 13, 2025

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

ALNY

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

<ul>
<li>-- Updating peak systemic&nbsp;mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT&#xAE; (avapritinib) launch and evolving SM prevalence estimates --</li>
<li>&nbsp;-- Expect to achieve $2 billion in AYVAKIT revenue by 2030 --</li>
<li>-- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained&nbsp;tryptase reductions exceeding 80% in Phase 1 healthy volunteer study --</li>
</ul>

BPMC

Reported Earlier, Blueprint Medicines Sees AYVAKIT 2024 Revenue At $475M–$480M (+130% YoY); Projects $4B SM Franchise Opportunity, Targets $2B AYVAKIT Revenue By 2030;

<ul>
<li>– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 –</li>
<li>– Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion –</li>
<li>– Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET –</li>
</ul>

EXEL

Reported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress

Ahead of President Joe Biden&#8216;s departure from office, a U.S. investigation has concluded that China engages in unfair&nbsp;practices to dominate the global&nbsp;shipbuilding industry. 
What Happened: The probe, initiated by&nbsp;U.S. Trade Representative Katherine Tai&nbsp;in April, was requested by the United Steelworkers and other&nbsp;unions under Section 301 of&nbsp;the Trade Act of 1974. This revelation could lead to potential penalties against China, according to&nbsp;Reuters&nbsp;on Monday. 
Investigators found that China uses&nbsp;financial support, barriers for foreign&nbsp;firms, forced technology transfer, and intellectual property theft to gain an advantage in shipbuilding, a source told Reuters. The report also highlights China&#8217;s suppression of labor costs in the maritime and logistics sectors. The findings could lead to&nbsp;tariffs or port fees on&nbsp;Chinese-built vessels.
The report indicates that China&#8217;s share in&nbsp;the $150 billion global shipbuilding&nbsp;market has grown from 5% in 2000&nbsp;to over 50% in 2023, largely due to government subsidies. Meanwhile, U.S. shipbuilders&#8217; market share has fallen below 1%. The U.S. Trade Representative&#8217;s office is expected to release the findings later this week, just before President Biden leaves office on Jan. 20.
This investigation follows previous&nbsp;efforts by the Biden administration&nbsp;to curb China&#8217;s influence through tariffs and export controls. Experts suggest that rebuilding the U.S. shipbuilding industry will require substantial investment and time.
Why It Matters: The U.S. probe into China&#8217;s shipbuilding practices has sparked significant controversy. Last year, the Chinese Ministry of Commerce <a href="https://www.benzinga.com/news/24/04/38312330/mistake-on-top-of-a-mistake-china-slams-us-probe-into-its-maritime-and-shipbuilding-sectors">criticized the investigation</a>, calling it a &#8220;mistake on top of a mistake,&#8221; asserting that China&#8217;s industrial growth is driven by technological innovation and market competition. 
Additionally, China is projected to surpass the <a href="https://www.benzinga.com/news/24/10/41142611/china-set-to-surpass-us-in-advanced-military-manufacturing-by-2035-report">U.S. in advanced technology </a>and military manufacturing by 2035, as reported by the South China Morning Post. Former vice-chairman of the National People&#8217;s Congress, Lu Yongxiang, emphasized that the decline of U.S. manufacturing is irreversible, suggesting a rapidly diminishing competitive edge for the U.S.
Meanwhile, Chinese policymakers are reportedly considering <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42473889/china-eyes-yuan-devaluation-to-counter-trumps-tariffs-will-it-work">allowing yuan devaluation</a> in 2025 to counter the economic impact of Trump&#8217;s proposed potential 60% tariff on Chinese imports.
Read More:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42931758/apple-staring-at-market-share-decline-in-china-amid-declining-iphone-shipments-top-analyst-flags-why-some-models-could-be-face-shipping-momentum-challenges">Apple Staring At Market Share Decline In China Amid Declining iPhone Shipments: Top Analyst Flags Why Some Models Could Be Face Shipping Momentum Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Global

General

US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms

<ul>
<li>2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1</li>
<li>Strong and Growing Demand for Galafold&#xAE; and Pombiliti&#xAE; + Opfolda&#xAE;</li>
<li>Total Revenue Growth of 17-24% at CER Expected in 2025</li>
<li>&gt;3,000 People Treated with an Amicus Therapy Today2</li>
</ul>

FOLD

Reported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales

Financial Update
<ul>
<li>Unaudited preliminary estimate of total full-year 2024 product revenue of ~€226 million:
<ul>
<li>SKYTROFA full-year 2024 revenue expected to be ~€202 million excluding sales deductions related to prior years (based on unaudited preliminary estimate of full-year 2024 SKYTROFA revenue of ~€197 million plus ~€5 million of sales deductions related to prior years).</li>
<li>YORVIPATH full-year 2024 unaudited preliminary revenue estimate of ~€29 million.</li>
</ul>
</li>
<li>Unaudited preliminary estimate of total full-year total 2024 revenue of ~€364 million
<ul>
<li>Includes $100 million Novo Nordisk milestone payment as non-product revenue.</li>
</ul>
</li>
<li>December 31, 2024 pro forma cash balance of ~€655 million (based on unaudited preliminary estimate of December 31, 2024 cash balance of €560 million plus expected payment from Novo Nordisk of $100 million).</li>
</ul>

ASND

Reported Earlier, Ascendis Pharma Projects €364M In 2024 Revenue, Reports €655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

ILMN

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

Arthur Hayes, co-founder of cryptocurrency exchange&nbsp;BitMEX and Chief Investment Officer at&nbsp;Maelstrom&nbsp;Fund, cast aspersions on MicroStrategy Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-powered Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy, forecasting challenging times for the firm when the top cryptocurrency loses volatility.
What happened: In an interview with Benzinga, Hayes slammed MicroStrategy&#8217;s volatility monetization play, which includes issuing convertible debt and other fixed-income securities to buy Bitcoin.
&#8220;The reason why these are attractive instruments is because the stock and the Bitcoin they purchase, are volatile,&#8221; Hayes said. 
Bitcoin has experienced a record-breaking run, rising by almost 50% in the last three months, helped by Donald Trump&#8217;s presidential victory. The rally has caused extreme upside volatility in Michael Saylor&#8217;s MicroStrategy, known more for its Bitcoin portfolio than the core software business. The stock has moved 62% in the last three months.
However, Hayes warned that things may not remain the same. &#8220;When the volatility of Bitcoin declines, most likely after a major crash, it will become difficult for MSTR to attract interest in these types of debt. At that point, the game is up.&#8221;
The Bitcoin bull said he won&#8217;t trade the MSTR stock at all, arguing that there are &#8220;better&#8221; ways to go long or short on Bitcoin.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Why It Matters: Hayes&#8217; remarks added to the growing concerns around MicroStrategy&#8217;s Bitcoin purchases.
Well-known economist Peter Schiff&nbsp;said previously that the company&#8217;s commitment to repay convertible note holders could be at a&nbsp;<a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy" target="_blank" rel="noreferrer noopener">potential risk</a>&nbsp;if Bitcoin drops significantly in value.
Martin Shkreli, known popularly as "Pharma Bro," <a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading">went to the extent of calling </a>the play a &#8220;big bubble," adding that he was short on MicroStrategy.
However, Anthony Scaramucci, CEO of investment firm&nbsp;SkyBridge Capital, has backed the strategy, arguing that the narrative that Bitcoin drops will force the company to liquidate its stash is overblown.
Price Action: At the time of writing, Bitcoin was exchanging hands at $93,573.37, down 0.90% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Shares of MicroStrategy closed 1.14% higher at $327.91 during Friday&#8217;s regular session. The stock has a consensus price target of $449.5 based on ratings by 12 analysts, with an average price target of $546.67 from Bernstein, TD Cowen, and Barclays.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

MSTR

Michael Saylor's MicroStrategy Will Struggle When Bitcoin's Volatility Falls, Says Arthur Hayes — I Would Not Trade MSTR At All

"2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and broadened our clinical stage pipeline," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "In 2025, we are poised to diversify our business further across multiple dimensions: our revenue, as we continue the launches of CASGEVY, ALYFTREK and potentially launch suzetrigine in acute pain; our pipeline, as we progress four potentially transformative medicines through pivotal trials; and our geographic footprint, as we expand both our commercial and clinical presence globally."

VRTX

Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025

<a href="https://www.globenewswire.com/Tracker?data=1RcWcJxSNSnWGASUIcrqEm5wmwbOegir3mS2aQtZmjriBWW6vEqZ7p1UrUtYBYb4OcFxpWZfuHTg3L5BahN98iB5FlLtdfjldpaUgr7jbbPgD_Vw1GEnAo1RH_QIML9nP5OiFLyJ5rGCG4wn7Z1dl3L7EYoDyUm-BtYEcCHd87MyYDRCwW8GgdQZlQgtcFyc1j4KXHxPQJEJwQqbQmQVduIETE2iccxtW9_5Kl5qSUx1T_EBeohyrsma6QVh7-L7GMS0saW-FI6xzsKgX6GSd37ML-qpg6MQjUJF4J1xRDBLhmnt9FoRvR7Ug8HeTrTmgFCk5nmy8f0ZWTwpaH3xzoJqKD2gBI-Avu6-B6kKS7479ZZe9RxIdYrGxHyWhQO7">MaxCyte, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Unaudited Fourth Quarter and Full Year 2024 Results
<ul>
<li>Core revenue in the fourth quarter is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in the fourth quarter of 2023</li>
<li>Core revenue for the full year is expected to be between $32.2 million and $32.4 million compared to $29.8 million for fiscal year 2023, representing 8 to 9% growth</li>
<li>SPL program-related revenue and Total Revenue for the fourth quarter and full year 2024 is expected to be reported in March 2025</li>
</ul>

Guidance

MXCT

MaxCyte Expects Q4 Core Revenue Of $8.3M-$8.5M Vs $7.2M YoY And FY24 Core Revenue Of $32.2M-$32.4M Vs $29.8M YoY

<ul>
<li>2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023</li>
<li>Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023</li>
<li>Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million</li>
</ul>

CSTL

Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments

&nbsp;CME Group, the world's leading derivatives marketplace, today announced that its international average daily volume (ADV) reached a record 7.8 million contracts in 2024, up 14% from 2023.&nbsp;Reflecting all trading reported outside the United States, this was driven by record growth in Energy up 31%, Metals up 27%, Agricultural up 25%, Interest Rate up 12% and Foreign Exchange products up 10% compared to the same period in 2023.

CME Group Hits Record 7.8 Million Daily International Contracts in 2024, up 14% YoY Driven by Energy and Metals Growth

<ul>
<li>Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia</li>
<li>Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing Authorization</li>
<li>Advancing Radiotherapeutic Assets including Alpha- and Auger-emitting Radioconjugates into Phase 1/2a Solid Tumor Studies</li>
</ul>

CLRB

Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development

Reported Earlier, Medical Properties Trust Supports Prospect's Chapter 11 Sale Plans For Connecticut Hospitals

Janus Henderson Small Cap Value Fund Q3 2024 Commentary

Janus Henderson Small-Mid Cap Value Fund Q3 2024 Commentary

Goldman Sachs analyst Julien Blouin initiated coverage of Cushman & Wakefield with a Sell rating and $15 price target The firm believes Cushman is ...

Cushman & Wakefield initiated with a Sell at Goldman Sachs

Columbia Small Cap Value Fund II Q3 2024 Commentary

JPMorgan raised the firm's price target on Cushman & Wakefield to $17 from $14 and keeps a Neutral rating on the shares. The firm remains construct...

Cushman & Wakefield price target raised to $17 from $14 at JPMorgan

Carillon Chartwell Small Cap Value Fund Q3 2024 Commentary

Jefferies analyst Peter Abramowitz downgraded Cushman & Wakefield (CWK) to Hold from Buy with a price target of $14, down from $18. The firm mainta...

Cushman & Wakefield downgraded to Hold from Buy at Jefferies

REITs set for 2025 rebound amid widest discount since GFC: Jefferies

The Justice Department, together with its state co-plaintiffs, said it filed an amended complaint today in its antitrust lawsuit against RealPage, ...

Cushman, Camden Property among landlords sued by Justice Department

Cushman & Wakefield, Camden Property, Blackstone added to DOJ's rental pricing suit

ABCB

APLS

BBWI

BYDGF

CBRE

CHRD

COLB

CTRE

CUBE

DINO

FBIN

HELE

HLIO

ICHR

INVH

JAAA

JBBB

JMBS

JSMD

JSML

LAMR

MCHP

MEOH

MTDR

MTUS

PIPR

PLXS

SILA

STAG

VNLA

WELL

WFRD

WTFC

Financing

Press Releases

Cushman & Wakefield and Greystone Arrange and Provide $33 Million in Construction Financing for New 210-Unit Multifamily Project in Downtown Spokane, WA

Cushman & Wakefield Releases In-Depth Report Providing Blueprint to Reimagine Cities

Cushman & Wakefield Names CoStar Group as National CRE Data Provider in Canada

Data Center Vacancy Falls to 3% in the Americas with 80% of New Construction Pre-Leased

Cushman & Wakefield to Release Third Quarter 2024 Earnings on November 4

Cushman & Wakefield Successfully Reprices 2030 Term Loan; Completes Prepayment to Fully Extinguish 2025 Term Loan

Cushman & Wakefield Reports Financial Results for the Third Quarter 2024

Cushman & Wakefield Named a 2025 Military Friendly® Top Five Employer

Cushman & Wakefield Adds Broker Trio to Atlanta Office Agency Leasing Team

Cushman & Wakefield: U.S. Industrial Quarterly Net Absorption Up 10.5% While Vacancy Inches Higher by 20 bps

Comments

Cushman & Wakefield

Cushman & Wakefield (CWK) オプション

Cushman & Wakefield (NYSE:CWK) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル